Skip to main content

Advertisement

SpringerLink
Log in

Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Braun DA, Burke KP, Van Allen EM (2016) Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res 22(23):5642–5650

    Article  CAS  Google Scholar 

  2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, Van ’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421

    Article  CAS  Google Scholar 

  3. Blum S, Martins F, Lübbert M (2017) Immunotherapy in adult acute leukemia. Leuk Res 60:63–73

    Article  CAS  Google Scholar 

  4. Leung AY, Tse E, Hwang YY, Chan TS, Gill H, Chim CS, Lie AK, Kwong YL (2013) Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. Am J Hematol 88(6):485–491

    Article  Google Scholar 

  5. Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471–2478

    Article  CAS  Google Scholar 

  6. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94–99

    Article  CAS  Google Scholar 

  7. Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP (2016) Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51(6):850–852

    Article  CAS  Google Scholar 

  8. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130(2):221–228

    Article  CAS  Google Scholar 

  9. Onizuka M, Kojima M, Matsui K, Machida S, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Nakamura N, Ando K (2017) Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol 106(1):141–145

    Article  CAS  Google Scholar 

  10. Minson A, Douglas G, Bilmon I, Grigg A (2019) Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD. Br J Haematol 184(5):840–844

    Article  Google Scholar 

  11. Chan TS, Khong PL, Kwong YL (2016) Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 95(11):1913–1915

    Article  Google Scholar 

  12. Kassa C, Reményi P, Sinkó J, Kállay K, Kertész G, Kriván G (2018) Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. Pediatr Transplant 22(8):e13302

    Article  Google Scholar 

  13. Sim JPY, Au-Yeung R, Kwong YL (2020) Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma. Ann Hematol 99(2):385–388

    Article  Google Scholar 

  14. Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M (2017) PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant 52(2):317–320

    Article  CAS  Google Scholar 

  15. Chan TSY, Sim JPY, Kwong YL (2017) Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation. Ann Hematol 96(9):1569–1572

    Article  CAS  Google Scholar 

  16. Kwong YL (2016) Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol 95(7):1191–1192

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China

    Joycelyn P. Y. Sim, Albert K. W. Lie & Yok-Lam Kwong

  2. Department of Diagnostic Radiology, Queen Mary Hospital, Pokfulam, Hong Kong, China

    Ming-Yen Ng

Authors
  1. Joycelyn P. Y. Sim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert K. W. Lie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-Yen Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yok-Lam Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Joycelyn Sim: study design, patient treatment, data analysis, manuscript writing and approval.

Albert Lie: patient treatment, manuscript approval.

Ming-Yen Ng: radiologic analysis, manuscript approval.

Yok-Lam Kwong: patient treatment, data analysis, manuscript writing and approval.

Corresponding author

Correspondence to Yok-Lam Kwong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

The patient gave informed consent to treatment.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sim, J.P.Y., Lie, A.K.W., Ng, MY. et al. Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab. Ann Hematol 100, 2399–2402 (2021). https://doi.org/10.1007/s00277-020-04042-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04042-1

Search

Navigation